PTC Therapeutics (PTCT) reported $1.7B in revenue for fiscal 2025, +114.5% year on year. That ranks #1432 by revenue among 2853 SEC filers and #130 in Healthcare. Net income was $683M, a net margin of 39.5%. Revenue has grown 40.2% a year on average since 2016 ($82.7M then). The fiscal 2025 balance sheet shows $2.9B in total assets, $985M in cash and $285M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $1.7B | +114.5% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $867M | +$1.2B | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $683M | +$1.0B | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $711M | +$819M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $8.9M | +36.3% | FY20252025-12-31 |
| Total assetsAssets | $2.9B | +70.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | −$205M | +$893M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $985M | +26.3% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $285M | +0.4% | FY20242024-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $273M | −$2.8M | Open → |
| Q2 20262026-06-30 | $361M | $83.5M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 2 of 161 companies compared | 39.5% | |
| Operating marginRank 2 of 160 companies compared | 50.1% | |
| R&D as share of revenueRank 18 of 102 companies compared | 26.3% | |
| Cash as share of revenueRank 6 of 160 companies compared | 56.9% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- PTC Therapeutics, Inc.
- Ticker
- PTCT
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001070081
Filings
- 10-QJul 30, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 19, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Integer HoldingsITGR | $1.9B | $103M |
| Healthcare ServicesHCSG | $1.8B | $59.1M |
| 111YI | $1.8B | −$3.2M |
| PTC TherapeuticsPTCT | $1.7B | $683M |
| Integra LifesciencesIART | $1.6B | −$517M |
| Lantheus HoldingsLNTH | $1.5B | $234M |
| National HealthcareNHC | $1.5B | $120M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=PTC Therapeutics — Key figures |url=https://companiesranked.com/en/company/ptc-therapeutics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). PTC Therapeutics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/ptc-therapeuticsBibTeX
@misc{companiesranked-en-company-ptc-therapeutics-2026,
author = {{CompaniesRanked}},
title = {{PTC Therapeutics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ptc-therapeutics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001104659-26-017575 · February 19, 2026
{{cite web |title=PTC Therapeutics — Key figures — 10-K (0001104659-26-017575) |url=https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-19}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.